Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Aurinia Pharmaceuticals Inc stock (AUPH) is currently trading at $14.37. Aurinia Pharmaceuticals Inc PE ratio is 6.77. Aurinia Pharmaceuticals Inc PS ratio (Price-to-Sales) is 6.59. Analyst consensus price target for AUPH is $17.00. WallStSmart rates AUPH as Moderate Buy.
- AUPH PE ratio analysis and historical PE chart
- AUPH PS ratio (Price-to-Sales) history and trend
- AUPH intrinsic value — DCF, Graham Number, EPV models
- AUPH stock price prediction 2025 2026 2027 2028 2029 2030
- AUPH fair value vs current price
- AUPH insider transactions and insider buying
- Is AUPH undervalued or overvalued?
- Aurinia Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- AUPH Piotroski F-Score and Altman Z-Score
- AUPH analyst price target and Smart Rating
Aurinia Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
AUPH Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Aurinia Pharmaceuticals Inc (AUPH)
AUPH trades at a significant discount to its Graham intrinsic value of $96.88, offering a 85% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Aurinia Pharmaceuticals Inc (AUPH) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, operating margin, revenue growth. Overall metrics suggest strong investment potential with favorable risk/reward.
Aurinia Pharmaceuticals Inc (AUPH) Key Strengths (6)
Every $100 of shareholder equity generates $60 in profit
Keeps $56 of every $100 in revenue after operating costs
Earnings per share surging 15073.00% year-over-year
Keeps $101 of every $100 in revenue as net profit
Strong revenue growth at 28.80% annually
55.68% held by institutions, strong professional interest
Supporting Valuation Data
Aurinia Pharmaceuticals Inc (AUPH) Areas to Watch (3)
Premium valuation at 6.6x annual revenue
Premium pricing at 3.2x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Aurinia Pharmaceuticals Inc (AUPH) Detailed Analysis Report
Overall Assessment
This company scores 68/100 in our Smart Analysis, earning a B- grade. Out of 9 metrics analyzed, 6 register as strengths (avg 9.3/10) while 3 fall into concern territory (avg 4.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Operating Margin, EPS Growth. Profitability is solid with Return on Equity at 59.90%, Operating Margin at 55.70%, Profit Margin at 101.50%. Growth metrics are encouraging with Revenue Growth at 28.80%, EPS Growth at 15073.00%.
The Bear Case
The primary concerns are Price/Sales, Price/Book, Market Cap. Some valuation metrics including Price/Sales (6.59), Price/Book (3.21) suggest expensive pricing.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Sales improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 59.90% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 28.80% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Return on Equity, Operating Margin) and negatives (Price/Sales, Price/Book). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AUPH Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AUPH's Price-to-Sales ratio of 6.59x trades at a deep discount to its historical average of 1460.95x (13th percentile). The current valuation is 100% below its historical high of 7587.08x set in Jan 2020, and 79% above its historical low of 3.69x in Apr 2024. Over the past 12 months, the PS ratio has expanded from ~4.6x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Aurinia Pharmaceuticals Inc (AUPH) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Aurinia Pharmaceuticals Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 283M with 29% growth year-over-year. Profit margins are strong at 101.5%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 29% YoY, reaching 283M. This pace significantly outperforms most BIOTECHNOLOGY peers.
ROE of 59.9% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Growth sustainability: can Aurinia Pharmaceuticals Inc maintain 29%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.59, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Aurinia Pharmaceuticals Inc.
Bottom Line
Aurinia Pharmaceuticals Inc offers an attractive blend of growth (29% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(34 last 3 months)
| Insider | Type | Shares |
|---|---|---|
KEENAN, GREG SVP, Chief Medical Officer | Sell | -8,069 |
| Insider | Type | Shares |
|---|---|---|
TANG, KEVIN Director | Buy | +184,208 |
| Insider | Type | Shares |
|---|---|---|
KEENAN, GREG SVP, Chief Medical Officer | Sell | -11,552 |
Data sourced from SEC Form 4 filings
Last updated: 10:09:49 AM
About Aurinia Pharmaceuticals Inc(AUPH)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.